Medivation

Medivation was an American biopharmaceutical company focused on rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation was headquartered in San Francisco, California, beginning operations in December 2004 with the acquisition of Medivation Neurology, Inc. Its final CEO was David Hung. Pfizer announced it would acquire the company in August 2016, and completed the acquisition in October 2016.

Medivation

Medivation was an American biopharmaceutical company focused on rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation was headquartered in San Francisco, California, beginning operations in December 2004 with the acquisition of Medivation Neurology, Inc. Its final CEO was David Hung. Pfizer announced it would acquire the company in August 2016, and completed the acquisition in October 2016.